Return to homepagePandemic Pact

A virus-free high-throughput platform for studying coronavirus replication inhibitors

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.043E+13

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2023

  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)

  • Principal Investigator

    dr D. Eggink PhD

  • Research Location

    Netherlands

  • Lead Research Institution

    Amsterdam UMC Locatie AMC

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The current COVID-19 crisis shows that we are not well prepared for the outbreak of new pandemic viruses. Vaccine development takes a lot of time and that is why antiviral drugs are our best defense against new viruses. Especially if they are able to inhibit a broad group of viruses. The current COVID-19 antiviral 'screens' require experiments with live viruses in a so-called BSL3 facility. Research Within this project, a screening method is proposed to test and optimize COVID-19 inhibitors that can be used in any laboratory. The platform is primarily used to screen new or improved drug candidates. In addition, the platform is used to investigate how COVID-19 activates the innate immune system. This process plays an important role in the course of the disease.